Outcomes after intervention for enteral nutrition in patients with amyotrophic lateral sclerosis in multidisciplinary clinics.
amyotrophic lateral sclerosis
enteral nutrition
malnutrition
prognostication
ventilatory dysfunction
Journal
Muscle & nerve
ISSN: 1097-4598
Titre abrégé: Muscle Nerve
Pays: United States
ID NLM: 7803146
Informations de publication
Date de publication:
02 May 2024
02 May 2024
Historique:
revised:
16
04
2024
received:
04
12
2023
accepted:
21
04
2024
medline:
2
5
2024
pubmed:
2
5
2024
entrez:
2
5
2024
Statut:
aheadofprint
Résumé
Patients with amyotrophic lateral sclerosis (ALS) are susceptible to malnutrition, with appropriate management of nutritional interventions an active area of investigation. We sought to determine the impact of gastrostomy tube placement in ALS patients, exploring the correlation between forced vital capacity (FVC), malnutrition, and perioperative complications. A retrospective review was performed of clinically diagnosed ALS patients treated at two multidisciplinary clinics (University of Kansas, University of Nebraska) from January 2009 to September 2020 who were referred for gastrostomy. Data collected included demographics, disease characteristics, and key gastrostomy related dates/outcomes. Two hundred thirty-nine patients were included with a median age of 65 years and median of 589 days from symptom onset to gastrostomy (interquartile range, 404-943). The population was predominantly Non-Hispanic White with bulbar-onset ALS. 30-day mortality was 4% and 30-day morbidity was 13%. Weight loss, body mass index, and predicted FVC at placement showed no increased 30-day morbidity or mortality association. Bulbar-onset ALS patients exhibited higher overall mortality postplacement than limb onset (odds ratio: 1.85, 95% confidence interval: 1.03-3.33). There was a 5% incidence of symptoms suggestive of refeeding syndrome. Rates of major/minor complications and 30-day mortality related to gastrostomy placement in our population were similar compared with prior studies in ALS. The lack of difference in outcomes based on FVC at procedure may suggest this is not predictive of outcome, or perhaps, high-quality perioperative respiratory management. Alternative reasons may account for the increased morbidity and mortality of gastrostomy placement in the ALS population.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIH HHS
ID : 10.13039/100000002
Pays : United States
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Cameron A, Rosenfeld J. Nutritional issues and supplements in amyotrophic lateral sclerosis and other neurodegenerative disorders. Curr Opin Clin Nutr Metab Care. 2002;5(6):631‐643.
Worwood AM, Leigh PN. Indicators and prevalence of malnutrition in motor neurone disease. Eur Neurol. 1998;40:159‐163.
Desport JC, Preux PM, Magy L, et al. Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis. Am J Clin Nutr. 2001;74(3):328‐334.
Brown RH, Al‐Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377(2):162‐172. doi:10.1056/NEJMra1603471
Braun MM, Osecheck M, Joyce NC. Nutrition assessment and management in amyotrophic lateral sclerosis. Phys Med Rehabil Clin N Am. 2012;23:751‐771.
Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence‐based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73(15):1218‐1226.
Miller RG, Rosenberg JA, Gelinas DF, et al. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence‐based review): report of the Quality Standards Subcommittee of the American Academy of neurology: ALS practice parameters task force. Neurology. 1999;52(7):1311‐1323.
Desport JC, Mabrouk T, Bouillet P, Perna A, Preux PM, Couratier P. Complications and survival following radiologically and endoscopically‐guided gastrostomy in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005;6(2):88‐93.
Chiò A, Finocchiaro E, Meineri P, Bottacchi E, Schiffer D. Safety and factors related to survival after percutaneous endoscopic gastrostomy in ALS. Neurology. 1999;53(5):1123‐1125.
Mazzini L, Corrà T, Zaccala M, Mora G, Del Piano M, Galante M. Percutaneous endoscopic gastrostomy and enteral nutrition in amyotrophic lateral sclerosis. J Neurol. 1995;242(10):695‐698.
Chiò A, Mora G, Leone M, et al. Early symptom progression rate is related to ALS outcome: a prospective population‐based study. 2002;59(1):99‐103.
Shaw AS, Ampong MA, Rio A, et al. Survival of patients with ALS following institution of enteral feeding is related to pre‐procedure oximetry: a retrospective review of 98 patients in a single centre. Amyotrophic Lateral Sclerosis. 2006;7:16‐21.
Mitsumoto H, Davidson M, Moore D, Gad N, Brandis M, Ringel S. Percutaneous endoscopic gastrostomy (PEG) in patients with ALS and bulbar dysfunction. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4(3):177‐185.
Mathus‐Vliegen LM, Louwerse LS, Merkus MP, Tytgat GN, Vianney de Jong JM. Percutaneous endoscopic gastrostomy in patients with amyotrophic lateral sclerosis and impaired pulmonary function. Gastrointest Endosc. 1994;40(4):463‐469.
RaeburnB F, Colville S, RobertJ S. Frequency, timing and outcome of gastrostomy tubes for amyotrophic lateral sclerosis/motor neurone disease. J Neurol. 2004;251(7):813‐817.
Dorst J, Dupuis L, Petri S, et al. Percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis: a prospective observational study. J Neurol. 2015;262(4):849‐858.
Gregory S, Siderowf A, Golaszewski AL, McCluskey L. Gastrostomy insertion in ALS patients with low vital capacity: respiratory support and survival. Neurology. 2002;58(3):485‐487.
Kak M, Issa NP, Roos RP, et al. Gastrostomy tube placement is safe in advanced amyotrophic lateral sclerosis. Neurol Res. 2017;39(1):16‐22.
Kasarskis EJ, Scarlata D, Hill R, Fuller C, Stambler N. A retrospective study of percutaneous endoscopic gastrostomy in ALS patients during the BDNF and CNTF trials phase III and ALS CNTF treatment study (ACTS) groups. J Neurol Sci. 1999;169:118‐125.
Gaspar R, Ramalho R, Coelho R, Andrade P, Goncalves MR, Macedo G. Percutaneous endoscopic gastrostomy placement under NIV in amyotrophic lateral sclerosis with severe ventilatory dysfunction: a safe and effective procedure. GE Port J Gastroenterol. 2023;30(1):61‐67.
Fasano A, Fini N, Ferraro D, et al. Percutaneous endoscopic gastrostomy, body weight loss and survival in amyotrophic lateral sclerosis: a population‐based registry study. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(3–4):233‐242.
Beggs K, Choi M, Travlos A. Assessing and predicting successful tube placement outcomes in ALS patients. Amyotrophic Lateral Sclerosis. 2010;11:203‐206.
Greenwood DI. Nutrition management of amyotrophic lateral sclerosis. Nutr Clin Pract. 2013;28:392‐399.
Bigard MA, Champigneulle B. A role for percutaneous endoscopic gastrostomy. Gastroenterol Clin Biol. 1987;11(10):659‐662.
Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS‐R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS study group (phase III). J Neurol Sci. 1999;169(1–2):13‐21.
Belafsky PC, Mouadeb DA, Rees CJ, et al. Validity and reliability of the eating assessment tool (EAT‐10). Ann Otol Rhinol Laryngol. 2008;117(12):919‐924.
Spataro R, Ficano L, Piccoli F, La Bella V. Percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis: effect on survival. J Neurol Sci. 2011;304(1–2):44‐48.
Prior‐Sánchez I, Herrera‐Martínez AD, Tenorio Jiménez C, et al. Gastrostomía endóscopica percutánea en esclerosis lateral amiotrófica; experiencia en un hospital de tercer nivel. Nutr Hosp. 2014;30(6):1289‐1294.
Shellikeri S, Karthikeyan V, Martino R, et al. The neuropathological signature of bulbar‐onset ALS: a systematic review. Neurosci Biobehav Rev. 2017;75:378‐392.
Bond L, Ganguly P, Khamankar N, et al. A comprehensive examination of percutaneous endoscopic gastrostomy and its association with amyotrophic lateral sclerosis patient outcomes. Brain Sci. 2019;9(9):223.
Kasarskis EJ, Tandan R. Why is nutrition vital for advancing ALS care and clinical research? Amyotroph Lateral Scler Frontotemporal Degener. 2023;24(5–6):359‐361.
Tandan R, Levy EA, Howard DB, et al. Body composition in amyotrophic lateral sclerosis subjects and its effect on disease progression and survival. Am J Clin Nutr. 2022;115(5):1378‐1392.
Kasarskis EJ, Mendiondo MS, Matthews DE, et al. Estimating daily energy expenditure in individuals with amyotrophic lateral sclerosis. Am J Clin Nutr. 2014;99(4):792‐803.
Scagnelli CN, Howard DB, Bromberg MB, et al. Hydration measured by doubly labeled water in ALS and its effects on survival. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(3–4):220‐231.
Mehanna HM, Moledina J, Travis J. Refeeding syndrome: what it is, and how to prevent and treat it. BMJ. 2008;336:1495‐1498.
da Silva JSV, Seres DS, Sabino K, et al. ASPEN consensus recommendations for refeeding syndrome. Nutrition in Clinical Practice. 2020;35(2):178‐195.
National Institute for Health and Care Excellence (NICE). Nutrition Support for Adults: Oral Nutrition Support, Enteral Tube Feeding and Parenteral Nutrition. National Institute for Health and Care Excellence (NICE); 2017 Accessed August 15, 2020. Available from: https://www.nice.org.uk/guidance/cg32